1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam

Bags Rights To Hypertension Therapy Zilebesiran

 
• By Kevin Grogan

The Swiss major is so keen to get access to Alnylam’s RNAi therapeutic targeting angiotensinogen that it is paying $310m upfront having only seen Phase I data. Some analysts are unsure if it is a good idea.

Roche
• Source: Roche

Roche Holding AG has taken the surprising step of jumping into the cardiovascular space and teamed up with Alnylam Pharmaceuticals Inc. to co-develop and co-commercialize zilebesiran, the RNA interference (RNAi) specialist's keenly-watched twice-yearly injection for hypertension.

The Swiss giant is paying $310m upfront while Alnylam is eligible to receive additional "substantial" near-term and development milestone payments...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.